New cancer pill SNV1521 enters human testing

NCT ID NCT06220864

Recruiting now Disease control Sponsor: Synnovation Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SNV1521 (oral tablet), DB-1310 (infusion), abiraterone (oral), darolutamide (oral)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.

What could go wrong

This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if SNV1521 will work. Side effects are possible, and the drug may not shrink tumors or improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AZ Groeninge
RECRUITING

Kortrijk, 8500, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
AZ Maria Middelares
RECRUITING

Ghent, 9000, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Institut Bergonie
RECRUITING

Bordeaux, 33076, France
Istituto Clinico Humanitas
RECRUITING

Milan, 20089, Italy
Istituto Europeo di Oncologia (IEO) (European Institute of Oncology)
RECRUITING

Milan, 20141, Italy
Linear Clinical Research
RECRUITING

Crawley, Western Australia, 6009, Australia
Monash Health
RECRUITING

Clayton, Victoria, 3168, Australia
NEXT Oncology - Barcelona
RECRUITING

Barcelona, 08023, Spain
NEXT Oncology - Hospital Quironsalud Madrid
RECRUITING

Madrid, 28223, Spain
Princess Alexandra Hospital
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Princess Margaret Hospital
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
START Center for Cancer Care
RECRUITING

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia
Smilow Cancer Hospital at Yale New Haven
RECRUITING

New Haven, Connecticut, 06511, United States
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia
The Institut Jules Bordet
RECRUITING

Brussels, 1070, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro
RECRUITING

Madrid, 28050, Spain
The University of Texas M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19144, United States
UNICANCER - Centre Leon-Berard (CLB)
RECRUITING

Lyon, 69008, France
University Center for Clinical Research Antwerp (UNICCRA)
RECRUITING

Edegem, 2650, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
Vall d'Hebron University Hospital
RECRUITING

Barcelona, 08035, Spain